Loading company…
Kentucky-based biotechnology company developing FCR001, an allogeneic cell therapy for transplant and autoimmune conditions.
Talaris, Inc., formerly known as Regenerex, was established in 2002 and is based in Kentucky, US. The company develops cellular therapies, led by FCR001, an allogeneic cell therapy in Phase 3 development for living donor kidney transplant recipients. Talaris raised USD 115 million in Series B funding in October 2020, co-led by Surveyor Capital and Viking Global Investors, and in May 2021 listed on Nasdaq under the ticker TALS in an IPO that raised USD 150.03 million.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in